Symptoms of crizotinib failure

Crizotinib, as an oral targeted drug for the treatment of non-small cell lung cancer, is widely used in the treatment ofALK positive non-small cell lung cancer. It reduces the growth and spread of tumors by blocking the activity of the ALK protein. However, when crizotinib fails, the most obvious manifestation is that the drug can no longer effectively control the disease. This may be because the drug has expired, has been contaminated and has changed the composition of the drug, or the patient has not followed the doctor's instructions and developed drug resistance. In this case, during reexamination, it will be found that the condition has not improved, and may even worsen.

After crizotinib fails, the patient's condition may further worsen. This shows that the original symptoms such as phlegm and wheezing are not relieved, but may intensify. In addition, more serious symptoms may occur, such as massive hemoptysis, dyspnea, stridor, etc. In extreme cases, tumors may spread within the cavity and even cause distant metastasis, seriously threatening the patient's life and health.

In addition to no therapeutic effect and worsening of the condition, crizotinib failure may also be accompanied by the emergence or intensification of a series of adverse reactions. These adverse reactions include, but are not limited to, digestive system symptoms such as nausea, vomiting, diarrhea, and constipation, as well as skin problems such as skin itching, rash, and urticaria. These reactions not only affect the patient's quality of life, but may also have further effects on the patient's physical condition.

It is worth noting that the resistance time to crizotinib varies from person to person and is usually related to the patient's genetic variation. Most patients with EGFR gene mutations will develop drug resistance about 8-14 months after receiving treatment, while patients with ALK gene mutations may have drug resistance for a slightly longer time. Therefore, patients should undergo regular examinations while taking crizotinib in order to detect drug resistance early and take appropriate treatment measures.